Chagas Watchdogs

Can screening dogs for Trypanosoma cruzi antibodies inform public health officials about the risk of Chagas disease to people?

Written byTracy Vence
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

ONCE BITTEN: Rachel Curtis-Robles, a PhD student also at A&M, examines kissing bugs.GABRIEL L. HAMERONCE BITTEN: Trevor Tenney, a second-year veterinary medical student at Texas A&M University, samples a dog at a shelterJESSICA RODRIGUEZDogs infected with Trypanosoma cruzi—the parasite that causes Chagas disease—may not show symptoms for years until, one day, their hearts fail. T. cruzi can infect animals that ingest or are bitten by assassin or “kissing” bugs, a variety of insect species in subfamily Triatominae that are widespread in the Americas. Left undetected and untreated, Chagas can become chronic and fatal in canines. Some humans infected with Chagas face a similar fate. According to the US Centers for Disease Control and Prevention (CDC), as many as 8 million people worldwide have Chagas disease—and most of them don’t know it.

The disease and its vectors are endemic to South and Central America, but both are spreading north, and confirmed cases of canine Chagas are on the rise across Texas, especially in southern portions of the state. Last year, the Texas Department of State Health Services made animal Chagas a notifiable condition, meaning veterinarians must report cases of the infectious disease to health officials within a week of confirming them.

In the past eight years, veterinarian Roy Madigan of the Animal Hospital of Smithson Valley in Spring Branch, Texas, has treated more than 100 dogs for Chagas disease. Madigan jokingly recalls having snoozed through a vet school parasitology lecture on T. cruzi in 1999, “because it was presented as ‘This is a Mexico and South [America–based] ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies